This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will detail its strategy to establish a leading gastrointestinal (GI) therapeutics company during its Investor Day today in New York City. This strategy leverages Ironwood’s strong development and commercial capabilities in addressing GI disorders as well as its pharmacologic expertise in guanylate cyclase (GC) pathways, all of which is based on Ironwood’s pioneering work bringing forward LINZESS, the first FDA-approved product in a new class of GI medicines called GC-C agonists.
“At Ironwood, we’ve had the privilege to successfully discover, develop and commercialize LINZESS, a medicine that is already helping hundreds of thousands of adult patients suffering from IBS-C or CIC. Our commercial and R&D teams are both executing at a very high level: we are working closely with our U.S. partner Forest to drive strong uptake of LINZESS, and we are also building a robust pipeline of potential treatments for other highly symptomatic GI conditions,” said Peter Hecht, chief executive officer of Ironwood Pharmaceuticals, Inc. “With LINZESS well on its way to becoming a leading GI brand, we have both the opportunity and the obligation to prioritize the areas of our business that we believe will maximize value for patients and shareholders. We will leverage our development and commercial expertise in an effort to address patient needs across the upper and lower gastrointestinal tract, and we will build on our deep pharmacologic expertise as we work to unlock value from our GC research platform, with a goal of advancing seven GI clinical development programs with multiple opportunities to generate proof of concept data over the next 24 months.”
To execute on its strategy, Ironwood will:
Leverage strong commercial capabilities
Advance robust GI pipeline and guanylate cyclase (GC) research
Prioritize investments in key value drivers
Ironwood and Forest Laboratories, Inc. introduced LINZESS in December 2012 for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). In its first year on the market, LINZESS has delivered strong results across key leading indicators for commercial success, including physician adoption and prescription rates, payer uptake and patient persistency.